Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | PGAM1 | P18669 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10135395 | 0.99 | ELANE (0.48) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL13018972 | 0.94 | ELANE (0.48) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL10135398 | 0.92 | ELANE (0.43) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL10182090 | 0.91 | PGAM1 (0.49) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL10181459 | 0.90 | ELANE (0.51) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL16167898 | 0.90 | ELANE (0.51) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL10135420 | 0.90 | ELANE (0.51) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL10135414 | 0.89 | NT5E (0.37) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL10135393 | 0.88 | ELANE (0.37) | ELANEALDH1A1HTTSMN1; SMN2TP53 | |
| SCHEMBL14723717 | 0.85 | MCL1 (0.39) | ELANEALDH1A1HTTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859235-B2 | Methods in cell cultures, and related inventions, employing certain additives | BASF SE (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8383088-B2 | Coumestan-like antioxidants and UV absorbants | BASF SE (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120164162-A1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BASF SE (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164162-A1 | METHODS IN CELL CULTURES, AND RELATED INVENTIONS, EMPLOYING CERTAIN ADDITIVES | BBOX1, NEFM, NQO1 | ELANE 509/4885ALDH1A1 152/4885HTT 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.